Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity

Radiotherapy (RT) has been used to control tumors by physically damaging DNA and inducing apoptosis; it also promotes antitumor immune responses via neoantigens release and augmenting immune-oncology agents to elicit systemic response. Tumor regression after RT can recruit inflammatory cells, such a...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Transl Oncol
Asıl Yazarlar: Younes, Ahmed I., Barsoumian, Hampartsoum B., Sezen, Duygu, Verma, Vivek, Patel, Roshal, Wasley, Mark, Hu, Yun, Dunn, Joe D., He, Kewen, Chen, Dawei, Menon, Hari, Masrorpour, Fatemeh, Gu, Meidi, Yang, Liangpeng, Puebla-Osorio, Nahum, Cortez, Maria Angelica, Welsh, James W.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Neoplasia Press 2020
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7750418/
https://ncbi.nlm.nih.gov/pubmed/33340886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2020.100983
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller